Assembly Biosciences is advancing its herpes drug to Phase II trials after it showed 94% antiviral efficacy in a Phase Ib ...

Clustered regularly interspaced short palindromic repeats (CRISPR)-based therapeutics are rapidly gaining traction for the management of infectious diseases. Programs targeting pathogens such as the ...

Growing research shows common herpes viruses may raise dementia risk, challenging previous skepticism and opening new paths ...

Assembly Biosciences, Inc.'s ABI-5366 showed strong interim phase 1b results in HSV-2 recurrent genital herpes patients.

A modified herpes virus (RP1) combined with immunotherapy showed promising results against advanced melanoma in a clinical ...

Assembly Biosciences (NASDAQ:ASMB) reported promising results from an early stage study of its experimental candidate, ...

The cold sore virus takes over its host’s transcription machinery to replicate itself. Inhibiting a host enzyme can halt ...

Cog11, placebo showed a significant advantage over valacyclovir at the end of the trial, but secondary measures of cognition ...

Many young adults make the choice to hook up and have sex in college, but they’re not always educated about how to prevent ...

Researchers from the University of Georgia (UGA), David Chu and Uma Singh, have developed a new molecule that may help treat ...